China Biotech Services Holdings Limited (HKG:8037)

HKG:8037 Revenue

China Biotech Services Holdings had revenue of 37.23M HKD in the half year ending June 30, 2026, with 14.72% growth. This brings the company's total for the last twelve months to 85.86M, up 36.45% year-over-year. In the year 2025, China Biotech Services Holdings had annual revenue of 73.50M with 4.25% growth. That makes China Biotech Services Holdings the 36,909th largest company in the world by revenue and 2,246th in Hong Kong.

• Revenue (ttm): 85.86M
• Revenue Growth: +36.45%
• P/S Ratio: 5.80
• Revenue / Employee: 517.25K
• Employees: 166
• Market Cap: 492.74M

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Medical and Health Related Services 39.61M 55.3%
• Insurance Brokerage 30.60M 42.8%
• Pharmaceutical Products 1.22M 1.7%
• Others 141.00K 0.2%

By Geography

Chart

• Hong Kong, China 70.51M 100.0%
• The PRC except Hong Kong, China 2.00K 0.0%

Fiscal year ended Dec 31, 2024 See the full HKG:8037 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	73.50M	2.99M	4.25%
Dec 31, 2024	70.51M	-141.48M	-66.74%
Dec 31, 2023	211.99M	-1.64B	-88.55%
Dec 31, 2022	1.85B	1.23B	196.83%
Dec 31, 2021	623.76M	-32.03M	-4.88%

Data Source: S&P Global Market Intelligence Last updated: Sep 29, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 19, 2026

Data Sources Report a data error